When is Pricing Unethical? Pharmaceuticals, Rideshares, Soft Drinks, and Travel Custom Case Solution & Analysis

Evidence Brief: Case Extraction

Financial Metrics

• Turing Pharmaceuticals (Daraprim): Price increased from 13.50 USD to 750 USD per tablet immediately following acquisition. This represents a 5,455% increase for a drug with no new research and development costs associated with the acquirer (Paragraph 4).
• Mylan (EpiPen): Price for a two-pack increased from approximately 100 USD in 2007 to over 600 USD by 2016. This is a 400% increase during a period where the product remained largely unchanged (Paragraph 6).
• Uber: Surge pricing multipliers during high-demand events or emergencies have reached 4x to 8x the base fare (Paragraph 12).
• Coca-Cola: Proposed temperature-sensitive vending machines were designed to increase prices as ambient temperature rose, though specific price points were not publicly disclosed before the project was shelved (Paragraph 15).

Operational Facts

• Market Structure: Pharmaceutical examples involve life-saving medications with limited or no immediate substitutes and high barriers to entry due to regulatory requirements (Paragraph 5).
• Dynamic Pricing Algorithms: Rideshare and travel industries utilize real-time data on supply and demand to adjust prices automatically. These systems function without manual oversight during rapid fluctuations (Paragraph 11).
• Geography: The case examines global firms operating primarily under US and European regulatory frameworks, where market-based pricing is generally legal but socially sensitive (Paragraph 2).

Stakeholder Positions

• Martin Shkreli (Turing CEO): Defended price hikes as a means to fund future research, stating that the company needed to maximize profit for shareholders (Paragraph 4).
• Heather Bresch (Mylan CEO): Attributed price increases to the complexity of the healthcare supply chain and the need to invest in awareness and access (Paragraph 7).
• Consumers/Patients: Expressed outrage through social media and congressional testimony, viewing price hikes on necessities as a violation of social contracts (Paragraph 8).
• Regulators: Increased scrutiny of pricing practices, leading to public hearings and proposed legislation to cap price increases on essential goods (Paragraph 18).

Information Gaps

• Actual production costs for Daraprim and EpiPen are not provided, making it difficult to calculate exact margins.
• The case lacks data on the specific revenue impact of the Coca-Cola temperature-pricing pilot before its cancellation.
• The exact threshold at which a price increase triggers a regulatory response is undefined.

Strategic Analysis

Core Strategic Question

How can organizations maximize revenue through dynamic or value-based pricing without breaching the ethical threshold that triggers brand erosion and regulatory intervention?

Structural Analysis

The conflict exists at the intersection of market efficiency and the Fairness Principle. Applying the Fairness-Necessity Framework reveals two distinct categories of pricing behavior:

• Discretionary Goods: In travel and soft drinks, consumers perceive dynamic pricing as a choice. A higher price for a hotel room or a cold soda is an inconvenience, not a threat to life. Market clearing prices here are generally accepted.
• Inelastic Necessities: In pharmaceuticals, the consumer cannot opt out. When the product is a life-saving necessity, the moral obligation to provide access supersedes the market right to maximize profit. The EpiPen and Daraprim cases failed because they treated a necessity as a discretionary luxury.

Strategic Options

Option 1: Capped Dynamic Pricing. Implement algorithmic guardrails that prevent prices from exceeding a pre-defined multiple of the base price, especially during emergencies or for essential goods.
Trade-offs: Limits short-term revenue upside but protects against catastrophic brand damage and legislative backlash.
Resources: Requires software updates and a dedicated ethics review board for pricing logic.

Option 2: Tiered Access Model. Maintain high prices for commercial or insured buyers while providing a low-cost or cost-plus tier for low-income or uninsured populations.
Trade-offs: Complex to administer and prone to arbitrage, but provides a moral defense against claims of exploitation.
Resources: Requires administrative infrastructure to verify eligibility.

Option 3: Cost-Plus Transparency. Commit to a transparent pricing model where prices are tied to production and R&D costs plus a fixed, fair margin.
Trade-offs: Lowest profit potential and exposes sensitive cost data to competitors.
Resources: Requires open-book accounting and public relations support.

Preliminary Recommendation

Organizations should adopt Option 1. The market will tolerate price fluctuations for convenience but will revolt against the exploitation of vulnerability. Establishing a 3x or 4x cap on surge pricing and a 10% annual limit on necessity price increases preserves the mechanism of dynamic pricing while respecting the social contract.

Implementation Roadmap

Critical Path

• Phase 1: Classification (Days 1-20). Categorize the entire product portfolio into Necessity or Discretionary segments based on consumer alternatives and health impact.
• Phase 2: Algorithmic Audit (Days 21-50). Review all automated pricing software. Insert hard-coded caps that trigger during periods of extreme demand or supply shocks.
• Phase 3: Stakeholder Communication (Days 51-75). Proactively publish the new pricing ethics charter. Brief investors on why these caps prevent long-term regulatory risk.
• Phase 4: Monitoring (Days 76-90). Establish a real-time alert system for any price movement exceeding two standard deviations from the mean.

Key Constraints

• Fiduciary Duty: Shareholders may view pricing caps as a failure to maximize value. Management must frame this as risk mitigation against future litigation.
• Algorithmic Complexity: In global markets, defining an emergency or a necessity varies by geography. A one-size-fits-all cap may fail in highly volatile currencies.

Risk-Adjusted Implementation

The primary risk is a competitor not following these ethical constraints and capturing short-term market share. To counter this, the firm should lead an industry-wide coalition to set standards, effectively making ethical pricing a competitive requirement rather than a solo disadvantage. Contingency plans must include a rapid-response communications team to explain any price spikes that occur despite the caps.

Executive Review and BLUF

BLUF

Ethical pricing is a requirement for long-term license to operate. The case studies of Turing and Mylan demonstrate that extreme price hikes on necessities lead to total brand destruction and invite aggressive regulation. Companies must distinguish between convenience-based dynamic pricing and necessity-based exploitation. We must implement a pricing framework that caps increases on essential goods and establishes algorithmic guardrails for discretionary products. This is not a moral concession; it is a strategic defense against the legislative intervention that follows public outrage. Failure to self-regulate will result in state-imposed price controls that are far more restrictive than voluntary caps.

Dangerous Assumption

The analysis assumes that regulators and the public behave rationally. In reality, public anger is often triggered by the perception of unfairness regardless of the underlying economic justification. Even a modest price increase can lead to a boycott if the timing coincides with a period of high social anxiety.

Unaddressed Risks

• Regulatory Contagion: A crackdown on pharmaceutical pricing in one jurisdiction often spreads to other sectors like insurance or housing, regardless of whether those sectors behaved ethically.
• Data Privacy: As pricing becomes more personalized based on consumer data, the risk shifts from price gouging to discriminatory pricing, which carries severe legal penalties.

Unconsidered Alternative

The team did not consider a Subscription Model for necessities. Instead of per-unit pricing, a flat monthly fee for access to essential drugs or services would decouple price from immediate demand, stabilizing revenue and eliminating the optics of price gouging during crises.

VERDICT: APPROVED FOR LEADERSHIP REVIEW